Femasys (NASDAQ:FEMY) CEO Kathy Lee-Sepsick Purchases 15,625 Shares of Stock

Femasys Inc. (NASDAQ:FEMY) CEO Kathy Lee-Sepsick bought 15,625 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the chief executive officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Femasys Trading Down 0.8%

Shares of NASDAQ:FEMY traded down $0.02 during midday trading on Tuesday, reaching $2.35. The company had a trading volume of 228,436 shares, compared to its average volume of 120,035. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. Femasys Inc. has a 1-year low of $2.29 and a 1-year high of $22.20. The firm has a market cap of $7.10 million, a price-to-earnings ratio of -0.44 and a beta of -2.08. The company has a fifty day simple moving average of $3.87 and a two-hundred day simple moving average of $7.49.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings data on Friday, May 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.33) by $1.43. The firm had revenue of $0.42 million for the quarter, compared to the consensus estimate of $0.77 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Institutional Investors Weigh In On Femasys

A number of institutional investors have recently modified their holdings of the stock. Kovack Advisors Inc. acquired a new stake in shares of Femasys during the 4th quarter valued at $27,000. HRT Financial LP purchased a new position in Femasys in the fourth quarter valued at about $30,000. Cetera Investment Advisers purchased a new position in Femasys in the fourth quarter valued at about $36,000. Osaic Holdings Inc. acquired a new position in Femasys in the second quarter worth approximately $45,000. Finally, State Street Corp increased its stake in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Wall Street Zen upgraded Femasys to a “hold” rating in a report on Saturday, June 13th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Femasys has a consensus rating of “Hold” and an average price target of $80.00.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.